[ad_1]
Oxford University is studying the use of a nasal spray version of the coronavirus vaccine, the MTI said in a university statement.
The experiment is still in its first phase, looking at the immune response to a vaccine called ChAdOx1 nCoV-19, jointly developed by AstraZeneca and the University of Oxford, when it is blown into a person’s nose. Thirty healthy volunteers between the ages of 18 and 40 participate in the trial.
Each volunteer is given the same vaccine that is currently used as a nasal spray injection and is tested for four months afterward.
Sandy Douglas, the study’s lead inspector, highlighted in a statement to the presentation:
Several immunologists are of the opinion that if the vaccine is administered directly to the site of viral infection, it may increase the protection provided by the vaccine.
During the trial, the vaccine is administered to participants using the same nasal spray device as products available in pharmacies, such as hay fever.
Nasal spray vaccines are already used successfully to prevent other diseases in the UK, such as school flu vaccines.
Sarah Gilbert, a professor of vaccine research at Oxford University, indicated at a hearing at the House of Commons Science and Technology Committee in London late last month that nasal spray or tablet vaccines are expected to appear between the coronavirus. vaccines in the future.
[ad_2]
